Azenta (BA3) Q3 2026 Earnings Report

The call reflected a cautious but constructive tone: the company delivered a better-than-expected quarter with solid organic revenue growth (9%), sequential profitability improvement (adjusted EBITDA margin up ~610 bps sequentially) and progress on strategic initiatives (AI-enabled biorepository deployment, modular stores, UKBC integration, and B Medical divestiture). However, meaningful near-term headwinds remain — notably gross margin pressure (overall and in Sample Management Solutions), quality remediation costs ($5M–$6M expected), ongoing Sanger secular decline, negative quarterly free cash flow, and a difficult Q4 comp. Management emphasized disciplined execution and a measured outlook. Overall, positives around execution and a stronger outlook are balanced by persistent margin and demand uncertainties.

Azenta updated its fiscal 2026 outlook, now expecting reported revenue of $613–$618 million and organic revenue roughly flat to up 1% year‑over‑year (improved from prior -2% to +1%); full‑year adjusted EBITDA is guided to $59–$62 million (Q4 adjusted EBITDA $20–$23 million) with Q4 organic revenue expected to decline low single digits versus a tough Q4 comp. Management expects full‑year free cash flow to improve ~10%–15% YoY, anticipates UK Biocentre will dilute margins by ~30 basis points, and reiterated remediation costs for automated stores of ~$5–$6 million for FY26 (about $1 million incurred in Q3). For context, Q3 revenue was $161 million (up 12% reported / 9% organic), Q3 adjusted EBITDA margin was ~11.4% (down 60 bps YoY, up 610 bps sequential), gross margin was 46.2% (down 140 bps), cash and equivalents were $529 million, and the company repurchased ~2.3 million shares for $50 million while completing the $63 million divestiture of B Medical Systems.